World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
45
Citations
7497
World Ranking
5024
National Ranking
155

Federico Pulido publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Federico Pulido sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 223 publications — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Federico Pulido D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Federico Pulido sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 45 D-Index — 10th percentile

10% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Federico Pulido is affiliated with Complutense University of Madrid in Spain. Their research primarily focuses on medicine, with a substantial body of work in immunology and microbiology. The key subfields of study include infectious diseases, virology, epidemiology, emergency medicine, and hepatology.

The main topics explored by Federico Pulido involve HIV/AIDS drug development and treatment, HIV research and treatment, HIV/AIDS research and interventions, as well as HIV-related health complications and treatments. Additional focus areas include Pneumocystis jirovecii pneumonia detection and treatment, hepatitis C virus research, and aspects related to HIV, drug use, and sexual risk.

Federico Pulido has contributed to research published in several journals, including:

  • Journal of Antimicrobial Chemotherapy (6 publications)
  • JAIDS Journal of Acquired Immune Deficiency Syndromes (4 publications)
  • HIV Medicine (3 publications)
  • Scientific Reports (3 publications)
  • EBioMedicine (3 publications)

Notable recent papers authored or coauthored by Federico Pulido include:

  • "2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0" (2020, HIV Medicine)
  • "Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study" (2020, The Lancet HIV)
  • "Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997-2017)" (2020, Scientific Reports)
  • "Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort" (2021, Clinical Microbiology and Infection)
  • "Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial" (2021, Infectious Diseases and Therapy)

Their research collaborations include frequent coauthors such as Rafael Rubio, Otilia Bisbal, Inmaculada Jarrín, Félix Gutiérrez, and David Rial-Crestelo.

Best Publications

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • A SHORT-TERM STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE

    Sven A. Danner;Andrew Carr;John M. Leonard;Leah M. Lehman

  • Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

    Francois Raffi;Anita Rachlis;Hans-Jürgen Stellbrink;W David Hardy

  • The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

    Jose R Arribas;Andrzej Horban;Jan Gerstoft;Gerdt Fätkenheuer

  • Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

    Hans Jürgen Stellbrink;Jacques Reynes;Adriano Lazzarin;Eugene Voronin

  • Sustained Virological Response to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus

    Juan Berenguer;Elena Rodríguez;Pilar Miralles;Miguel A. Von Wichmann

  • Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.

    Federico Pulido;José R Arribas;Rafael Delgado;Esther Cabrero

  • Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

    José R Arribas;Pierre-Marie Girard;Roland Landman;Judit Pich

  • Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

    José R Arribas;Federico Pulido;Rafael Delgado;Alicia Lorenzo

  • Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.

    Daniel Podzamczer;Elena Ferrer;Pochita Sanchez;José M. Gatell

  • Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.

    Deanna Kerrigan;Andrea Mantsios;Miguel Gorgolas;Maria Luisa Montes

  • Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

    Jean-Michel Molina;Kathleen Squires;Paul E Sax;Pedro Cahn

  • Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study.

    Jacques Reynes;Roger Trinh;Federico Pulido;Ruth Soto-Malave

  • Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B

    Laguna F;López-Vélez R;Pulido F;Salas A

  • Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

    Jose R Arribas;Rafael Delgado;Alberto Arranz;Rosa Muñoz

  • Genetic barrier to resistance for dolutegravir.

    Josep M Llibre;Federico Pulido;Federico García;Miguel García Deltoro

  • 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.

    L Ryom;A Cotter;R De Miguel;C Béguelin

  • Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis

    Sandra Mathis;Bettina Khanlari;Federico Pulido;Martin T. Schechter

  • Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.

    Federico Pulido;Esteban Ribera;María Lagarde;Ignacio Pérez-Valero

  • Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.

    Chloe Orkin;Jean-Michel Molina;Eugenia Negredo;José R Arribas

  • Cohorte RIS de pacientes con infección por VIH sin tratamiento antirretroviral previo (CoRIS): metodología y primeros resultados

    Ana María Caro-Murillo;Jesús Castilla;Santiago Pérez-Hoyos;José M Miró

  • Relapse of Tuberculosis After Treatment in Human Immunodeficiency Virus—Infected Patients

    Federico Pulido;Jose-Maria Peña;Rafael Rubio;Santiago Moreno

  • Incidence of Acquired Immunodeficiency Syndrome-Associated Opportunistic Diseases and the Effect of Treatment on a Cohort of 1115 Patients Infected with Human Immunodeficiency Virus, 1989–1997

    Francisco-Javier San-Andrés;Rafael Rubio;Jesús Castilla;Federico Pulido

  • Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.

    Maria Luisa Montes;Federico Pulido;Carlos Barros;Emilia Condes

  • Infection of sand flies by humans coinfected with Leishmania infantum and human immunodeficiency virus.

    R Molina;J M Lohse;F Pulido;F Laguna

  • Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results

    Jacques Reynes;Adebayo Lawal;Federico Pulido;Ruth Soto-Malave

Frequent Co-Authors

Jose R. Arribas
Jose R. Arribas Hospital Universitario La Paz
Juan Berenguer
Juan Berenguer Hospital General Universitario Gregorio Marañón
Santiago Moreno
Santiago Moreno Hospital Universitario Ramón y Cajal
Antonio Rivero
Antonio Rivero Instituto Maimónides de Investigación Biomédica de Córdoba
Pere Domingo
Pere Domingo Autonomous University of Barcelona
Hernando Knobel
Hernando Knobel Autonomous University of Barcelona
Josep Mallolas
Josep Mallolas University of Barcelona
Eugenia Negredo
Eugenia Negredo University of Vic - Central University of Catalonia
Daniel Podzamczer
Daniel Podzamczer Bellvitge University Hospital
Juan A. Pineda
Juan A. Pineda Spanish National Research Council

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to diverse career opportunities, often complemented by specialized training in health information management and medical coding. For those interested in healthcare data, pursuing a cahiim accredited health information management degree online can provide essential skills required to oversee patient information systems and medical records.

Career prospects in this field are promising, with roles such as health information managers enjoying competitive pay. To better understand the financial aspects, reviewing a health information manager salary overview can give insights into potential earnings and advancement.

For microbiology graduates looking to quickly enter the healthcare administrative side, fast online medical billing and coding certification programs offer accelerated paths to certification, enabling swift transition into roles managing billing processes and coding medical records.

Moreover, those aiming for broader knowledge in medical sciences may explore various online medical degrees that provide flexible learning options while balancing work or research commitments.

Best Scientists Citing Federico Pulido

Trending Scientists